Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc. has reported a net loss of $752,383 for Q1 2024, in line with expectations, and is embracing AI technology for drug development in cancer treatment. The company has secured exclusive access to a proprietary AI platform for DNA-damage response targets and expanded research collaborations, signaling a strategic advancement. These efforts aim to propel Rakovina’s novel therapies from the discovery phase through to human clinical trials in partnership with pharmaceutical entities.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
